X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
1. Acetonide 21-acetate, Fluocinolone
2. Fapg, Fluocinonide
3. Fluocinolide
4. Fluocinolone Acetonide 21 Acetate
5. Fluocinolone Acetonide 21-acetate
6. Fluocinonide Fapg
7. Klariderm
8. Lidemol
9. Lidex
10. Lyderm
11. Metosyn
12. Novoter
13. Tiamol
14. Topsym
15. Topsyn
16. Topsyne
1. 356-12-7
2. Lidex
3. Fluocinolide
4. Fluocinolone Acetonide Acetate
5. Vanos
6. Lonide
7. Fluocinolide Acetate
8. Fluonex
9. Lidex-e
10. Metosyn
11. Topsyn
12. Fluocinonidum [inn-latin]
13. Fluocinonide Emulsified Base
14. Fluocinonido [inn-spanish]
15. Fluocinolone Acetonide 21-acetate
16. Lidex E
17. Lyderm
18. 2w4a77ypan
19. Mls000028476
20. Pregna-1,4-diene-3,20-dione,21-(acetyloxy)-6,9-difluoro-11-hydroxy-16,17-[(1-methylethylidene)bis(oxy)]-,(6a,11b,16a)-
21. Fluocinonido
22. Fluocinonidum
23. Smr000058331
24. Dsstox_cid_25307
25. Dsstox_rid_80793
26. Dsstox_gsid_45307
27. C26h32f2o7
28. Nsc-101791
29. Fluocinonide [usan:ban:inn:jan]
30. Vanos (tn)
31. Einecs 206-597-6
32. Lidex (tn)
33. Unii-2w4a77ypan
34. Nsc 101791
35. Ncgc00016436-01
36. Cas-356-12-7
37. Fluocinonide(vanos)
38. Prestwick_1066
39. Fluocinonide (vanos)
40. 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, Cyclic 16,17-acetal With Acetone, 21-acetate
41. Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-6,9-difluoro-11-hydroxy-16,17-((1-methylethylidene)bis(oxy))-, (6alpha,11beta,16alpha)-
42. Fluocinonide [usan:usp:inn:ban:jan]
43. Opera_id_1780
44. Prestwick0_000774
45. Prestwick1_000774
46. Prestwick2_000774
47. Prestwick3_000774
48. Fluocinonide [mi]
49. Fluocinonide [inn]
50. Fluocinonide [jan]
51. Fluocinonide [usan]
52. Schembl4262
53. Chembl1501
54. Fluocinonide [vandf]
55. Bspbio_000848
56. Fluocinonide [mart.]
57. Pregna-1,4-diene-3,20-dione, 6-alpha, 9-difluoro-11-beta,16-alpha,17,21-tetrahydroxy-, Cyclic17-acetal With Acetone, 21-acetate
58. Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, Cyclic 16,17-acetal With Acetone, 21-acetate
59. Fluocinonide [usp-rs]
60. Fluocinonide [who-dd]
61. Spbio_002787
62. Bpbio1_000934
63. Chebi:5109
64. Gtpl7078
65. Dtxsid8045307
66. Fluocinonide (jp17/usp/inn)
67. Fluocinonide, >=98% (hplc)
68. Fluocinonide [orange Book]
69. Hms1570k10
70. Hms2097k10
71. Hms2234h04
72. Hms3259n05
73. Hms3714k10
74. Fluocinonide [usp Impurity]
75. 6.alpha.,9-difluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, Cyclic 16,17-acetal With Acetone, 21-acetate
76. Hy-b0485
77. Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-6,9-difluoro-11-hydroxy-16,17-((1-methylethylidene)bis(oxy))-, (6.alpha.,11.beta.,16.alpha.)-
78. Zinc3977978
79. Tox21_110438
80. S2608
81. Akos015896516
82. Tox21_110438_1
83. Ac-2071
84. Bcp9000697
85. Ccg-220774
86. Db01047
87. Nc00621
88. Ncgc00022398-03
89. Ncgc00022398-05
90. Bs-17093
91. C07007
92. D00325
93. 356f127
94. Sr-01000003097
95. Q5462791
96. Sr-01000003097-3
97. W-106660
98. Brd-k57886322-001-03-4
99. Brd-k57886322-001-12-5
100. Fluocinonide, United States Pharmacopeia (usp) Reference Standard
101. 2-((2s,6as,6br,7s,8as,8bs,11ar,12as,12bs)-2,6b-difluoro-7-hydroxy-6a,8a,10,10-tetramethyl-4-oxo-1,2,4,6a,6b,7,8,8a,11a,12,12a,12b-dodecahydro-8bh-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-8b-yl)-2-oxoethyl Acetate
102. 2-[(1s,2s,4r,8s,9s,11s,12r,13s,19s)-12,19-difluoro-11-hydroxy-6,6,9,13-tetramethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosa-14,17-dien-8-yl]-2-oxoethyl Acetate
| Molecular Weight | 494.5 g/mol |
|---|---|
| Molecular Formula | C26H32F2O7 |
| XLogP3 | 3.2 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 4 |
| Exact Mass | 494.21160968 g/mol |
| Monoisotopic Mass | 494.21160968 g/mol |
| Topological Polar Surface Area | 99.1 Ų |
| Heavy Atom Count | 35 |
| Formal Charge | 0 |
| Complexity | 1070 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 9 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 8 | |
|---|---|
| Drug Name | Fluocinonide |
| PubMed Health | Fluocinonide (On the skin) |
| Drug Classes | Corticosteroid, Strong |
| Drug Label | Fluocinonide Cream 0.1% contains fluocinonide, a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents. Fluocinonide h... |
| Active Ingredient | Fluocinonide |
| Dosage Form | Ointment; Cream; Gel; Solution |
| Route | Topical |
| Strength | 0.05%; 0.1% |
| Market Status | Prescription |
| Company | Teva; Taro; Fougera; Glenmark Generics; Fougera Pharms; G And W Labs; Perrigo Israel |
| 2 of 8 | |
|---|---|
| Drug Name | Fluocinonide emulsified base |
| PubMed Health | Fluocinonide (On the skin) |
| Drug Classes | Corticosteroid, Strong |
| Drug Label | VANOS (fluocinonide) Cream, 0.1% contains fluocinonide, a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents. Fluoc... |
| Active Ingredient | Fluocinonide |
| Dosage Form | Cream |
| Route | Topical |
| Strength | 0.05% |
| Market Status | Prescription |
| Company | Teva; Taro; Fougera Pharms |
| 3 of 8 | |
|---|---|
| Drug Name | Lidex |
| PubMed Health | Fluocinonide (On the skin) |
| Drug Classes | Corticosteroid, Strong |
| Active Ingredient | Fluocinonide |
| Dosage Form | Solution |
| Route | Topical |
| Strength | 0.05% |
| Market Status | Prescription |
| Company | Cnty Line Pharms |
| 4 of 8 | |
|---|---|
| Drug Name | Vanos |
| Active Ingredient | Fluocinonide |
| Dosage Form | Cream |
| Route | Topical |
| Strength | 0.1% |
| Market Status | Prescription |
| Company | Medicis |
| 5 of 8 | |
|---|---|
| Drug Name | Fluocinonide |
| PubMed Health | Fluocinonide (On the skin) |
| Drug Classes | Corticosteroid, Strong |
| Drug Label | Fluocinonide Cream 0.1% contains fluocinonide, a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents. Fluocinonide h... |
| Active Ingredient | Fluocinonide |
| Dosage Form | Ointment; Cream; Gel; Solution |
| Route | Topical |
| Strength | 0.05%; 0.1% |
| Market Status | Prescription |
| Company | Teva; Taro; Fougera; Glenmark Generics; Fougera Pharms; G And W Labs; Perrigo Israel |
| 6 of 8 | |
|---|---|
| Drug Name | Fluocinonide emulsified base |
| PubMed Health | Fluocinonide (On the skin) |
| Drug Classes | Corticosteroid, Strong |
| Drug Label | VANOS (fluocinonide) Cream, 0.1% contains fluocinonide, a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents. Fluoc... |
| Active Ingredient | Fluocinonide |
| Dosage Form | Cream |
| Route | Topical |
| Strength | 0.05% |
| Market Status | Prescription |
| Company | Teva; Taro; Fougera Pharms |
| 7 of 8 | |
|---|---|
| Drug Name | Lidex |
| PubMed Health | Fluocinonide (On the skin) |
| Drug Classes | Corticosteroid, Strong |
| Active Ingredient | Fluocinonide |
| Dosage Form | Solution |
| Route | Topical |
| Strength | 0.05% |
| Market Status | Prescription |
| Company | Cnty Line Pharms |
| 8 of 8 | |
|---|---|
| Drug Name | Vanos |
| Active Ingredient | Fluocinonide |
| Dosage Form | Cream |
| Route | Topical |
| Strength | 0.1% |
| Market Status | Prescription |
| Company | Medicis |
A topical anti-inflammatory product for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
FDA Label
Fluocinonide is a potent glucocorticoid steroid used topically as anti-inflammatory agent for the treatment of skin disorders such as eczema. It mediates its effects to relieve itching, redness, dryness, crusting, scaling, inflammation, and discomfort associated with inflammatory skin conditions.
Anti-Inflammatory Agents
Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)
Glucocorticoids
A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. (See all compounds classified as Glucocorticoids.)
Anti-Allergic Agents
Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)
C - Cardiovascular system
C05 - Vasoprotectives
C05A - Agents for treatment of hemorrhoids and anal fissures for topical use
C05AA - Corticosteroids
C05AA11 - Fluocinonide
D - Dermatologicals
D07 - Corticosteroids, dermatological preparations
D07A - Corticosteroids, plain
D07AC - Corticosteroids, potent (group iii)
D07AC08 - Fluocinonide
Absorption
The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. In general, percutaneous absorption is minimal.
Route of Elimination
Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys.
Fluocinonide is a potent glucocorticoid steroid used topically as anti-inflammatory agent for the treatment of skin disorders such as eczema. Fluocinonide binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. Cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In another words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Like other glucocorticoid agents Fluocinolone acetonide acts as a physiological antagonist to insulin by decreasing glycogenesis (formation of glycogen). It also promotes the breakdown of lipids (lipolysis), and proteins, leading to the mobilization of extrahepatic amino acids and ketone bodies. This leads to increased circulating glucose concentrations (in the blood). There is also decreased glycogen formation in the liver.
Market Place
